A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FFS / failure-free survival

[Related PubMed/MEDLINE]
Total Number of Papers: 365
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FFS  (>> Co-occurring Abbreviation)
Long Form:   failure-free survival
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy. chemo-PRT, chemo-WART, chemoRT, HR, OCCC, OS, PRT, WART
2020 Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis. AA, allo-HSCT, HR, IST, ORR, OS, RR
2020 Better Failure-Free Survival and Graft-versus-Host Disease-Free/Failure Free Survival with Fludarabine-Based Conditioning in Stem Cell Transplantation for Aplastic Anemia in Children. AA, CY, Flu, GVHD, IST, OS, SCT
2020 Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. CI, DCR, HR, mCRC, mFFS, ORR, PFS, RBWT
2020 Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. aGVHD, cGVHD, HID-HSCT, MSD, OS, SAA, URD
2020 Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. HRQoL, SAA, UCB
2020 Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - A meta analysis. aGVHD, cGVHD, CI, haplo-HSCT, IST, OS, SAA
2020 Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. FL, FLIPI, HDT/ASCT, HR, OS, POD, POD24-PI, R-CHOP
2020 Excision and Primary Anastomosis for Isolated, Short, Anastomotic Strictures in Transmen. EPA, HR
10  2020 Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma. CC, CCRT, CCRT, DMFS, IC, LANPC, LRFS, OS, RRFS
11  2020 Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. AC, CCRT, CI, DMFS, HR, IC, LANPC, LRRFS, OS, PSM
12  2020 Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine. ATG, BMMNC, OS, SAA
13  2020 Long-term outcomes of moderately hypofractionated radiotherapy (67.5Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis. OS, PCSS
14  2020 Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. IQR, IRE, ISUP, mpMRI, PCa, PSA, QOL, TTMB
15  2020 Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia. DBA, HSCT, MAC, OS, RIC
16  2020 Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. CR, CR, OS, PR
17  2020 RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. ADT, AR, CRPC, PC, PSA, RGS2
18  2020 The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. EFS, MCyR, MR, OS, TFS
19  2020 The predictive value of serum myeloma protein in solitary plasmacytoma. LC, MMFS, OS
20  2020 Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma. cHL
21  2019 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. CI, HR, IMRT, LFFS, NPC, OS
22  2019 Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. AAP, ADT, HR, mHNPC, OS, PFS
23  2019 Adjuvant chemoradiotherapy vs. radiotherapy alone in early-stage high-risk endometrial cancer: a systematic review and meta-analysis. CRT, DMR, FIGO, LRR, OS, RCTs, RT
24  2019 Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. aUC, HR, OS
25  2019 Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. cGVHD, CIBMTR, GSS, NRM, OS
26  2019 Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). ICT, ICTOS, LANPC
27  2019 Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. CI, IQR, mpMRI, NCCN, PSA
28  2019 Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. ADT, mHSPC, OS, PSA
29  2019 HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound. FT, GS, HIFU, PCa, PSA
30  2019 Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. HID, HSCT, IST, KPS, OS, SAA
31  2019 Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population. ACA, CI, CML, HR, PFS
32  2019 Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases. PERCIST, SBRT, SINS, spMets, VCF
33  2019 Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy. BMI, CCRT, DFFS, LRFFS, NPC, OS, ROC, RTT, TPF, TTT
34  2019 Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. CR, DMFS, EBV, IMRT, LRRFS, NPC, OS
35  2019 Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. ADT, CI, FAME, HRs, mHSPC, PFS
36  2019 Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. CI, FR, OS, RMS, TPZ, UR
37  2019 Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. ASCT, CI, DLBCL, OS, R-PECC
38  2019 Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. CNS, CNS-RFS, DLBCL, OS, PVRL, VRL
39  2019 Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. cGVHD
40  2019 Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. CI, eGFR, MVA, PMF, RI
41  2019 The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. cGVHD, cGVHD-FFS
42  2019 The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. CML, ELN, MMR, OR, OS, TKI, WR
43  2019 Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy. CR, HPV, IR, ND, OPC, OS, PET/CT, PV
44  2019 Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. allo-HSCT, GVHD, MNC, OS, SAA
45  2019 [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase]. CCyR, CML-CP, MMR, OS, PFS
46  2019 [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics]. CCyR, CML-CP, MMR, OS, PFS
47  2018 A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. CI, HIFU, IQR, mpMRI, PCa, PSA
48  2018 Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. ADT, CrI, mHSPC, OS, SUCRA
49  2018 Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. anti-PDGFRA, cGVHD
50  2018 Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter? AS, HR, mpMRI, PI-RADS
51  2018 Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. ALP, CCO, CI, HR, OS, PLR, SOCC
52  2018 FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. CHOP, FL, HR, IHC
53  2018 Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. ChSa, OS, TFS
54  2018 Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. ITP, PSE
55  2018 Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. CCRT, IC, LANPC
56  2018 Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. AYAs, COG, HL, OS
57  2018 Patterns of relapse for children with localized intracranial ependymoma. CI, CRT, IMRT, OS
58  2018 Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy. CCRT, D-FFS, ERCC1, L-FFS, NPC, OS, ROC
59  2018 Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. DMFS, EBV, GTV, HR, LRRFS, NPC, OS, SIB-IMRT
60  2018 Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. CI, CR, MMT-95, OR, OS, PD, PR, RMS, SIOP
61  2018 The role of N-Myc gene amplification in neuroblastoma childhood tumour - single-centre experience. NBL, OS
62  2018 What kind of patients with castration-naive prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. ABI, ADT, CNPC, DOC, ECOG, ICTRP, OS
63  2017 ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. AP/BC, CML, MR, OS
64  2017 Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. ACAs, CP-CML, EFS, OS, TFS, TKIs
65  2017 Comparison of three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy in the treatment of cervical esophageal carcinoma. IMRT, OS, VMAT
66  2017 Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. DS, HL, iPET, IVS, SQ
67  2017 Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. cCR, IMRT, LRFFS, NPC, OS
68  2017 Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. IMPACT, MTT, OS, PI3K
69  2017 Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. CI, HR, IFRT, MALT, OALDs
70  2017 Long-term outcomes of 95 children with moderate aplastic anemia treated with horse antithymocyte globulin and cyclosporine. ATG, CI, IST, MAA
71  2017 Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. AFP, HCC, IL, RT
72  2017 Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers. DFS, MPHNSCC, MTV, OS, prePET, TLG
73  2017 Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. LRC, OS
74  2017 Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. IRS, OS, VAC
75  2017 Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. ADT, IQR, RPA, SMs, SRT
76  2017 Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. DMFS, IMRT, LRFS, NPC, OS, RRFS
77  2017 The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. AITL, OS, PTCL-NOS
78  2017 Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. CR, HR, NPC, PR, SD
79  2017 Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. aGVHD, cGVHD, HID, HIDs, HSCT, IST, MRDs, OS, SAA
80  2016 Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. AA, BMT, cGVHD, EBMT, IST
81  2016 Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma. AC, CCRT, DMFS, LRRFS, NPC, OS
82  2016 Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. CML-CP, EFS, OS, TFS, TKIs
83  2016 Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. CPM, IRS, VA, VAC, VTC
84  2016 Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. DFFS, NPC, OS
85  2016 Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. HRs, HT, IQR, RT
86  2016 Invasive micropapillary carcinoma of the breast had poor clinical characteristics but showed no difference in prognosis compared with invasive ductal carcinoma. DMFS, IDC, IMPC, LRFS, OS
87  2016 Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. HCL, MRD
88  2016 Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. CCI, DLBCL, OS, R-CEOP, R-CHOP, R-CVP, R-EPOCH
89  2016 Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer. LS-SCLC, OS, PCI
90  2016 Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. CC, DMFS, IC, IMRT, LRFS, OS
91  2016 Predicting chronic GVHD outcomes: are we there yet? GVHD, NIH, OS
92  2016 Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. GVHD, NIH, NRM, OS
93  2016 Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. CR, MCL, MDS/AML, OS
94  2016 Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. SBRT
95  2016 The effects of hemoglobin levels and their interactions with cigarette smoking on survival in nasopharyngeal carcinoma patients. Hb, LR-FFS, NPC, OS
96  2016 The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. ADT, aHR, CI, EBRT, IR-PrCa
97  2016 Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. DFFS, LRFFS, NPC, OS
98  2015 Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. DMFS, IC, IMRT, LA-NPC, LRFS, OS
99  2015 Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma. D-FFS, NPC, OS, TMA
100  2015 Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. HPV, IHC, ISH, LSCC, OS